A monotonic and prognostic genomic signature from fibroblasts for colorectal cancer initiation, progression, and metastasis

Molecular Cancer Research

Volumn 12, Issue 9, 2014, Pages 1254-1266

  Berdiel Acer, Mireia ^a,c   Cuadras, Daniel ^b   Díaz Maroto, Natalia Guillén ^a   Sanjuan, Xavier ^b   Serrano, Teresa ^b   Berenguer, Antoni ^b   Moreno, Victor ^b   Gonçalves Ribeiro, Samuel ^a   Salazar, Ramon ^b   Villanueva, Alberto ^a   Molleví, David G ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; COLORECTAL CANCER; FIBROBLAST; GENE; GENE EXPRESSION; GENE ONTOLOGY; HUMAN; HUMAN CELL; LOW RISK PATIENT; METASTASIS; PRIMARY TUMOR; TUMOR MICROENVIRONMENT; CARCINOGENESIS; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; HUMAN GENOME; METABOLISM; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE;

TRANSCRIPTOME;

CARCINOGENESIS; COLORECTAL NEOPLASMS; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TRANSCRIPTOME;

EID: 84904602423     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0121     Document Type: Article

References (50)

1. Lee AH, Dublin EA, Bobrow LG. Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast. J Pathol 1999;187:285-90.
2. Elenbaas B, Weinberg RA. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res 2001;264:169-84.
3. Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011; 29:17-24.
4. O'Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 2010;28:3937-44.
5. Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 2010;138:958-68.
6. Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, Desai J, et al. Metastasis-associated gene expression changes predict poor outcomes in patients with dukes stage B and C colorectal cancer. Clin Cancer Res 2009;15:7642-51.
7. Rinn JL, Bondre C, Gladstone HB, Brown PO, Chang HY. Anatomic demarcation by positional variation in fibroblast gene expression programs. PLoS Genet 2006;2:e119.
8. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004;2:E7.
9. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 2005;102:3738-43.
10. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011;17:320-9.
11. Wilson CL, Miller CJ. Simpleaffy: a BioConductor package for Affymetrix Quality Control and data analysis. Bioinformatics 2005;21:3683-5.
12. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
13. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002;99:6567-72.
14. Abba M, Laufs S, Aghajany M, Korn B, Benner A, Allgayer H. Look who's talking: deregulated signaling in colorectal cancer. Cancer Genomics Proteomics 2012;9:15-25.
15. Okazaki S, Ishikawa T, Iida S, Ishiguro M, Kobayashi H, Higuchi T, et al. Clinical significance of UNC5B expression in colorectal cancer. Int J Oncol 2012;40:209-16.
16. de Sousa EMF, Colak S, Buikhuisen J, Koster J, Cameron K, de Jong JH, et al. Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell 2011;9:476-85.
17. Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Cespedes MV, et al. Dependency of colorectal cancer on a TGFbeta- driven program in stromal cells for metastasis initiation. Cancer Cell 2012;22:571-84.
18. Kim YH, Lee HC, Kim SY, Yeom YI, Ryu KJ, Min BH, et al. Epigenomic analysis of aberrantly methylated genes in colorectal cancer identifies genes commonly affected by epigenetic alterations. Ann Surg Oncol 2011;18:2338-47.
19. Xiao W, Wang J, Li H, Guan W, Xia D, Yu G, et al. Fibulin-1 is downregulated through promoter hypermethylation and suppresses renal cell carcinoma progression. J Urol 2013;190:291-30
20. Cheng YY, Jin H, Liu X, Siu JM, Wong YP, Ng EK, et al. Fibulin 1 is downregulated through promoter hypermethylation in gastric cancer. Br J Cancer 2008;99:2083-7.
21. Hibi K, Mizukami H, Saito M, Kigawa G, Nemoto H, Sanada Y. FBN2 methylation is detected in the serum of colorectal cancer patients with hepatic metastasis. Anticancer Res 2012;32:4371-4.
22. Tsunoda S, Smith E, De Young NJ, Wang X, Tian ZQ, Liu JF, et al. Methylation of CLDN6, FBN2, RBP1, RBP4, TFPI2, and TMEFF2 in esophageal squamous cell carcinoma. Oncol Rep 2009;21:1067-73.
23. Kim TO, Park J, Kang MJ, Lee SH, Jee SR, Ryu DY, et al. DNA hypermethylation of a selective gene panel as a risk marker for colon cancer in patients with ulcerative colitis. Int J Mol Med 2013;31: 1255-61.
24. Dannenberg LO, Chen HJ, Tian H, Edenberg HJ. Differential regulation of the alcohol dehydrogenase 1B (ADH1B) and ADH1C genes by DNA methylation and histone deacetylation. Alcohol Clin Exp Res 2006;30:928-37.
25. Huang YW, Jansen RA, Fabbri E, Potter D, Liyanarachchi S, Chan MW, et al. Identification of candidate epigenetic biomarkers for ovarian cancer detection. Oncol Rep 2009;22:853-61.
26. Mithani SK, Smith IM, Califano JA. Use of integrative epigenetic and cytogenetic analyses to identify novel tumor-suppressor genes in malignant melanoma. Melanoma Res 2011;21:298-307.
27. Richards KL, Zhang B, Sun M, Dong W, Churchill J, Bachinski LL, et al. Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers. Cancer 2011;117:606-17.
28. Weiss D, Stockmann C, Schrodter K, Rudack C. Protein expression and promoter methylation of the candidate biomarker TCF21 in head and neck squamous cell carcinoma. Cell Oncol 2013;36:213-24
29. Louie E, Chen XF, Coomes A, Ji K, Tsirka S, Chen EI. Neurotrophin-3 modulates breast cancer cells and the microenvironment to promote the growth of breast cancer brain metastasis. Oncogene 2013;32: 4064-77.
30. Moravcikova E, Krepela E, Prochazka J, Rousalova I, Cermak J, Benkova K. Down-regulated expression of apoptosis-associated genes APIP and UACA in non-small cell lung carcinoma. Int J Oncol 2012;40:2111-21.
31. Ford CE, Jary E, Ma SS, Nixdorf S, Heinzelmann-Schwarz VA, Ward RL. The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells. PLoS ONE 2013;8:e54362.
32. Chang YT, Wu CC, Shyr YM, Chen TC, Hwang TL, Yeh TS, et al. Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection. PLoS ONE 2011;6:e20029.
33. Fujita A, Shida A, Fujioka S, Kurihara H, Okamoto T, Yanaga K. Clinical significance of Rho GDP dissociation inhibitor 2 in colorectal carcinoma. Int J Clin Oncol 2012;17:137-42.
34. Li X, Wang J, Zhang X, Zeng Y, Liang L, Ding Y. Overexpression of RhoGDI2 correlates with tumor progression and poor prognosis in colorectal carcinoma. Ann Surg Oncol 2012;19:145-53.
35. Cho HJ, Baek KE, Kim IK, Park SM, Choi YL, Nam IK, et al. Proteomicsbased strategy to delineate the molecular mechanisms of RhoGDI2- induced metastasis and drug resistance in gastric cancer. J Proteome Res 2012;11:2355-64.
36. Berdiel-Acer M, Bohem ME, Lopez-Doriga A, Vidal A, Salazar R, Martinez-Iniesta M, et al. Hepatic carcinoma-associated fibroblasts promote an adaptative response in colorectal cancer cells that inhibit proliferation and apoptosis: nonresistant cells die by nonapoptotic cell death. Neoplasia 2011;13:931-46.
37. Huijbers A, Tollenaar RA, GW VP, Zeestraten EC, Dutton S, McConkey CC, et al. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann Oncol 2013;24:179-85
38. Chang HY, Chi JT, Dudoit S, Bondre C, van de Rijn M, Botstein D, et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci U S A 2002;99:12877-82.
39. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008;14:518-27.
40. Jia Z, Rahmatpanah FB, Chen X, Lernhardt W, Wang Y, Xia XQ, et al. Expression changes in the stroma of prostate cancer predict subsequent relapse. PLoS ONE 2012;7:e41371.
41. Navab R, Strumpf D, Bandarchi B, Zhu CQ, Pintilie M, Ramnarine VR, et al. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci U S A 2011;108:7160-5.
42. Gao Q, Wang XY, Qiu SJ, Zhou J, Shi YH, Zhang BH, et al. Tumor stroma reaction-related gene signature predicts clinical outcome in human hepatocellular carcinoma. Cancer Sci 2011;102:1522-31.
43. Illemann M, Hansen U, Nielsen HJ, Andreasen PA, Hoyer-Hansen G, Lund LR, et al. Leading-edge myofibroblasts in human colon cancer express plasminogen activator inhibitor-1. Am J Clin Pathol 2004;122:256-65.
44. Sieuwerts AM, Martens JW, Dorssers LC, Klijn JG, Foekens JA. Differential effects of fibroblast growth factors on expression of genes of the plasminogen activator and insulin-like growth factor systems by human breast fibroblasts. Thromb Haemost 2002;87: 674-83.
45. Pesson M, Volant A, Uguen A, Trillet K, De La Grange P, Aubry M, et al. A gene expression and pre-mRNA splicing signature that marks the adenoma-adenocarcinoma progression in colorectal cancer. PLoS ONE 2014;9:e87761.
46. Okano M, Yamamoto H, Ohkuma H, Kano Y, Kim H, Nishikawa S, et al. Significance of INHBA expression in human colorectal cancer. Oncol Rep 2013;30:2903-8.
47. Kudo Y, Ogawa I, Kitajima S, Kitagawa M, Kawai H, Gaffney PM, et al. Periostin promotes invasion and anchorage-independent growth in the metastatic process of head and neck cancer. Cancer Res 2006;66:6928-35.
48. Fukushima N, Kikuchi Y, Nishiyama T, Kudo A, Fukayama M. Periostin deposition in the stroma of invasive and intraductal neoplasms of the pancreas. Mod Pathol 2008;21:1044-53.
49. Yan W, Shao R. Transduction of a mesenchyme-specific gene periostin into 293T cells induces cell invasive activity through epithelial-mesenchymal transformation. J Biol Chem 2006;281: 19700-8.
50. De Sousa EMF, WangX, Jansen M, Fessler E, Trinh A, de Rooij LP, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 2013;19:614-8.